Evaluation of biosimilars for formulary inclusion: Factors for consideration by P&T committees

P and T

Volumn 40, Issue 10, 2015, Pages 680-689

  Lee Ventola, C ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOSIMILAR AGENT; ERYTHROPOIETIN;

ARTICLE; AWARENESS; DRUG COST; DRUG LABELING; DRUG PACKAGING; DRUG STORAGE; DRUG SURVEILLANCE PROGRAM; GOVERNMENT REGULATION; HEALTH CARE; IMMUNOGENICITY; INFORMATION TECHNOLOGY; PATIENT EDUCATION; PRESCRIPTION DRUG DIVERSION; REIMBURSEMENT; THERAPEUTIC COMMUNITY;

EID: 84944719160     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: primer for the health-system pharmacist. Am J Health Syst Pharm 2013;70(22):2004-2017.
2. Griffith N, McBride A, Stevenson JG, Green L. Formulary selection criteria for biosimilars: Considerations for US health-system pharmacists. Hosp Pharm 2014;49(9):813-825.
3. American Pharmacists Association. The biosimilar pathway: Where will it lead us? Pharmacy Today, December 2011:67-76.
4. Hoffman JM, Li E, Stevenson JG. Preparing for biosimilars: scientific, regulatory, and practice management issues for pharmacists [webcast]. 47th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition, Las Vegas, Nevada, December 3, 2012. Available at: http://www.ashpadvantage.com/biosimcentral/midyear.html. Accessed September 14, 2015.
5. Tadlock C. Challenges in the anticipation of biosimilars: How must a P&T committee gear up? Manag Care Interface 2007;20(4):12,14.
6. Falit BP, Singh SC, Brennan TA. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers. Health Aff 2015;34(2):294-301.
7. Hoffman JM, Thomas EL, Dombrowski SR. A health system pharmacist’s guide to biosimilars: regulatory, scientific, and practical considerations. American Society of Health-System Pharmacists. 2013. Available at: http://www.ashpadvantage.com/biosimcentral/docs/biosimcentralguidelines.pdf. Accessed June 30, 2015.
8. Martinusen DJ, Lo C, Marin JG, et al. Potential impact of subsequent entry biologics in nephrology practice in Canada. Can J Kidney Health Dis 2014;1:32.
9. Fernandez-Lopez S, Kazazz D, Bashir M, McLaughlin T. Assessment of pharmacists’ views on biosimilar naming conventions. JMCP 2015;21(3):188-195.
10. Medical Daily. Novartis wins FDA approval for Zarxio, first biosimilar drug in the US. March 6, 2015. Available at: http://www.medicaldaily.com/novartis-wins-fda-approval-zarxio-first-biosimilar-drug-us-324672. Accessed July 8, 2015.
11. Regulatory Affairs Professional Society. After three year delay, FDA finalizes guidance documents on biosimilarity. Available at: http://www.raps.org/Regulatory-Focus/News/2015/04/28/22058/After-Three-Year-Delay-FDA-Finalizes-Guidance-Documents-on-Biosimilarity. Accessed July 8, 2015.
12. Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res 2011:3;29-36.
13. Rana JB, Chang DY. Pharmacist perception of biosimilar agents in the U.S. Pharmacy Purchas Prod 2012;9(7):8.
14. Simoens S, Verbeken G, Huys I. Biosimilars and market access: a question of comparability and costs? Targ Oncol 2012;7(4):227-231.
15. Reinke T. Biosimilars might not measure up to health plan expectations. Manag Care 2012;21(10):12-13.
16. National Conference of State Legislatures. State laws and legislation related to biologic medications and substitution of biosimilars. Available at: http://www.ncsl.org/research/health/state-lawsand-legislation-related-to-biologic-medications-and-substitutionof-biosimilars.aspx. Accessed September 16, 2015.
17. Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 2012;28(6):1053-1058.
18. Calo-Fernández B, Martínez-Hurtado J. Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals 2012;5(12):1393-1408.
19. Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Cancer Network 2011;9(suppl 4):S1-S22.
20. Calvo B, Zuniga L. The U.S. approach to biosimilars: The longawaited FDA approval pathway. Biodrugs 2012;26(6):357-361.
21. Blackstone E, Fuhr J. Innovation and competition: Will biosimilars succeed? Biotechnol Healthcare 2012;9(1):24-27.
22. Barlas S. President Obama reopens debate on patented biologics: Will the FDA quickly define an abbreviated pathway for biosimilars? P&T 2011;36(4):178.
23. Food and Drug Administration. Purple book: lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm. Accessed July 8, 2015.
24. Barlas S. FDA readies new guidance and user fee program for biosimilars: Drug interchangeability and user fees are contentious issues the FDA must resolve. Is the FDA up to the task? Biotechnol Healthcare 2012;9(2):28-29.
25. Hirsch BR, Lyman GH. Biosimilars: Are they ready for prime time in the United States? J Natl Compr Cancer Network 2011;9:934-943.
26. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther 2012;91(3):405-417.
27. Nick C. The U.S. Biosimilars Act: Challenges facing regulatory approval. Pharm Med 2012:26(3):145-152.
28. Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures—2012. Am J Health Syst Pharm 2012;69(5):405-421.
29. Ventola CL. Biosimilars: Part 1: proposed regulatory criteria for FDA approval. P&T 2013;38(5):270-274, 277, 287
30. American Society of Hospital Pharmacists. Final 2015 Policy Recommendations. Available at: http://www.ashp.org/DocLibrary/Policy/HOD/CouncilReports.aspx. Accessed July 8, 2015.